Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan in Russian HER2+ Breast Cancer Patients
NCT07281001Recruiting
- Sponsor
- N.N. Blokhin Russian Cancer Research Center
- Start
- Dec 2025
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab deruxtecan in breast cancer, sponsored by N.N. Blokhin Russian Cancer Research Center. Primary endpoint: Progression-Free Survival at 6 weeks. Started Dec 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07281001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281001.